Search results for "Pharmacology and Therapeutics"

showing 4 items of 4 documents

Vascular Dysfunction in Experimental Diabetes Is Improved by Pentaerithrityl Tetranitrate but Not Isosorbide-5-Mononitrate Therapy

2011

OBJECTIVE Diabetes is associated with vascular oxidative stress, activation of NADPH oxidase, and uncoupling of nitric oxide (NO) synthase (endothelial NO synthase [eNOS]). Pentaerithrityl tetranitrate (PETN) is an organic nitrate with potent antioxidant properties via induction of heme oxygenase-1 (HO-1). We tested whether treatment with PETN improves vascular dysfunction in the setting of experimental diabetes. RESEARCH DESIGN AND METHODS After induction of hyperglycemia by streptozotocin (STZ) injection (60 mg/kg i.v.), PETN (15 mg/kg/day p.o.) or isosorbide-5-mononitrate (ISMN; 75 mg/kg/day p.o.) was fed to Wistar rats for 7 weeks. Oxidative stress was assessed by optical methods and o…

Blood GlucoseMalemedicine.medical_specialtyXanthine OxidaseEndocrinology Diabetes and MetabolismVasodilator AgentsOxidative phosphorylationIsosorbide Dinitratemedicine.disease_causeWeight GainNitric oxideDiabetes Mellitus Experimentalchemistry.chemical_compoundEnosInternal medicineInternal MedicinemedicineAnimalsPentaerythritol TetranitrateGene SilencingEndothelial dysfunctionRats WistarXanthine oxidaseGTP CyclohydrolaseNADPH oxidasebiologyNADPH Oxidasesmedicine.diseasebiology.organism_classificationStreptozotocinPharmacology and TherapeuticsRatsOxidative StressEndocrinologychemistryVasoconstrictionbiology.proteinEndothelium VascularReactive Oxygen SpeciesOxidative stressHeme Oxygenase-1medicine.drugDiabetes
researchProduct

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain.

2020

ObjectiveObservations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.Research design and methodsDeidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were desc…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypoglycemialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusmedicineHumans030212 general & internal medicine1506GlycemicBlood glucose monitoringmedicine.diagnostic_testbusiness.industryBlood Glucose Self-MonitoringEmerging Technologies Pharmacology and Therapeuticsmedicine.diseaseDiabetes Mellitus Type 1GlucosehypoglycemiaSpainCardiologyglycemic controlblood glucose monitoringbusinessReal world dataBMJ open diabetes researchcare
researchProduct

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study

2021

ObjectivesThe aim was to use routine data available at a patient’s admission to the hospital to predict polypharmacy and drug–drug interactions (DDI) and to evaluate the prediction performance with regard to its usefulness to support the efficient management of benefits and risks of drug prescriptions.DesignRetrospective, longitudinal study.SettingWe used data from a large multicentred pharmacovigilance project carried out in eight psychiatric hospitals in Hesse, Germany.ParticipantsInpatient episodes consecutively discharged between 1 October 2017 and 30 September 2018 (year 1) or 1 January 2019 and 31 December 2019 (year 2).Outcome measuresThe proportion of rightly classified hospital epi…

DrugHospitals PsychiatricLongitudinal studymedicine.medical_specialtymedia_common.quotation_subjectHealth informaticslaw.invention03 medical and health sciencesPharmacovigilance0302 clinical medicinelawRisk FactorsGermanyPharmacovigilanceMedicineHumans1723Drug Interactions030212 general & internal medicine1506Longitudinal StudiesMedical prescriptionPsychiatryhealth informaticsmedia_commonRetrospective StudiesPolypharmacyClinical pharmacologyReceiver operating characteristicbusiness.industryRGeneral MedicinePharmacology and Therapeuticspsychiatry030227 psychiatryPharmaceutical PreparationsMedicineclinical pharmacologybusinessBMJ Open
researchProduct

Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for…

2018

IntroductionRoux-en-Y gastric bypass (GBP) is associated with changes in cardiometabolic risk factors and bioavailability of drugs, but whether these changes are induced by calorie restriction, the weight loss or surgery per se, remains uncertain. The COCKTAIL study was designed to disentangle the short-term (6 weeks) metabolic and pharmacokinetic effects of GBP and a very low energy diet (VLED) by inducing a similar weight loss in the two groups.Methods and analysisThis open, non-randomised, three-armed, single-centre study is performed at a tertiary care centre in Norway. It aims to compare the short-term (6 weeks) and long-term (2 years) effects of GBP and VLED on, first, bioavailability…

OncologyMale030226 pharmacology & pharmacylaw.inventionTertiary Care Centers0302 clinical medicineWeight losslawRisk FactorsProtocol1506Omeprazolemedia_commonClinical Trials as TopicClinical pharmacologyNorwayArea under the curveGeneral MedicineObesity MorbidPharmaceutical PreparationsCardiovascular DiseasescardiologyBody CompositionFemalemedicine.symptommedicine.drugDrugmedicine.medical_specialtymedia_common.quotation_subjectGastric Bypassbasic sciencesBiological Availability030209 endocrinology & metabolism03 medical and health sciencesPharmacokineticsInternal medicineWeight LossmedicineHumansRosuvastatinPharmacokinetics1723Caloric Restrictionbusiness.industryPharmacology and TherapeuticsBioavailabilityLinear Modelsclinical pharmacologybusinessBiomarkers
researchProduct